Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2026-02-28 @ 8:47 PM
Study NCT ID:
NCT02122003
Status:
TERMINATED
Last Update Posted:
2017-11-22
First Post:
2014-04-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Second Line Sorafenib After Pazopanib in Patients With RCC
Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
GP2
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None